MAR-GALANTAMINE ER CAPSULE (EXTENDED RELEASE)

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

GALANTAMINE (GALANTAMINE HYDROBROMIDE)

Disponible des:

MARCAN PHARMACEUTICALS INC

Codi ATC:

N06DA04

Designació comuna internacional (DCI):

GALANTAMINE

Dosis:

16MG

formulario farmacéutico:

CAPSULE (EXTENDED RELEASE)

Composición:

GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16MG

Vía de administración:

ORAL

Unidades en paquete:

30

tipo de receta:

Prescription

Área terapéutica:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0144660004; AHFS:

Estat d'Autorització:

CANCELLED POST MARKET

Data d'autorització:

2021-05-10

Fitxa tècnica

1
PRODUCT MONOGRAPH
PR
MAR-GALANTAMINE ER
galantamine hydrobromide extended release capsules
8 mg, 16 mg, 24 mg galantamine base
Cholinesterase Inhibitor
Marcan Pharmaceuticals Inc.
Date of Revision:
77 Auriga Drive, Unit# 4
January 15, 2018
Ottawa, ON, CANADA
K2E 7Z7
Control No.: 212078
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
.................................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................................
3
ADVERSE REACTIONS
............................................................................................................................
7
DRUG INTERACTIONS
...........................................................................................................................
12
DOSAGE AND ADMINISTRATION
......................................................................................................
14
OVERDOSAGE
.........................................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
16
STORAGE AND STABILITY
..................................................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................................
20
PART II: SCIENTIFIC INFORMATION
..............................................................................................